Welcome to our dedicated page for GRAIL news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on GRAIL stock.
GRAIL reports news on its healthcare business focused on early cancer detection through the Galleri multi-cancer early detection blood test. The company uses next-generation sequencing, population-scale clinical studies, machine learning, software and automation within a targeted methylation-based platform designed to detect and identify multiple cancer types in earlier stages.
Recurring updates include Galleri revenue and test-volume trends, clinical data from programs such as NHS-Galleri and PATHFINDER 2, regulatory and evidence-generation activity, health-system access initiatives, commercial partnerships, conference presentations, equity incentive grants and governance changes. Company announcements also describe how its platform may support screening and precision oncology uses, including risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring and recurrence monitoring.
GRAIL (GRAL) granted employment inducement restricted stock units to new non-executive employees under Nasdaq Listing Rule 5635(c)(4), as of September 3, 2026.
The awards cover an aggregate of 55,867 RSUs tied to GRAIL common stock, issued to 59 recently hired non-executive employees as a material inducement to join the company. The RSUs were granted under GRAIL's Inducement Equity Incentive Plan and its standard restricted stock award agreement. The plan is used only for individuals who were not previously employed by GRAIL, or who return after a bona fide break in service. The RSUs vest over approximately four years, with 25% vesting on August 31, 2027 and the remaining portions vesting on each one-year anniversary thereafter, subject to continued employment with GRAIL or its affiliates.
GRAIL (Nasdaq: GRAL) announced that its management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14, 2026, at 11:30 a.m. ET. A live and replay webcast will be available via the investor relations section of GRAIL's website for at least 30 days.
GRAIL (Nasdaq: GRAL) announced that the FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on September 23, 2026 to review the Premarket Approval (PMA) application for its Galleri® multi-cancer early detection (MCED) blood test.
Galleri is designed to detect cancer-specific methylation patterns in blood, including cancers without existing screening, and to predict the cancer signal origin to guide diagnostic evaluation. According to GRAIL, the PMA focuses on test performance and safety data from 25,490 consented participants in the US-based PATHFINDER 2 study with one year of follow-up, and from more than 70,000 participants in the intervention arm of the first-year prevalent screening round of the NHS-Galleri randomized, controlled trial. Galleri was designated a Breakthrough Device by the FDA in 2018, and the submission also includes an analysis comparing earlier Galleri versions with the updated PMA version.
GRAIL (Nasdaq: GRAL) reported Q2 2026 total revenue of $44.7 million, up 26% year-over-year, driven by Galleri test revenue of $42.6 million, up 24%, on more than 61,000 tests, a 35% volume increase. First-half 2026 Galleri revenue reached $82.5 million with over 117,000 tests, rising 30% and 42% year-over-year, respectively.
Net loss for Q2 was $110.2 million, gross loss was $12.6 million, non-GAAP adjusted gross profit was $21.6 million, and adjusted EBITDA was $(90.3) million. Cash, cash equivalents and short-term marketable securities totaled $861.6 million, supported by a $110 million equity financing with Samsung entities.
GRAIL highlighted detailed NHS-Galleri and PATHFINDER 2 study results showing higher early-stage cancer detection and reduced late-stage diagnoses in certain cancers, expanded U.S. access through a Priority Health collaboration, and is anticipating an FDA advisory committee in the fall to review its Galleri PMA submission.
GRAIL (Nasdaq: GRAL) announced that company management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11 at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through the investor relations section of GRAIL's website, with the replay archived for at least 30 days.
GRAIL (Nasdaq: GRAL) will release its second quarter 2026 financial results after the market close on Wednesday, August 5, 2026. Company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to review the results and discuss business progress.
According to GRAIL, live and replay webcasts will be accessible via the investor relations section at investors.grail.com. Interested participants are asked to register for the live event in advance and join at least ten minutes before the scheduled start.
GRAIL (Nasdaq: GRAL) announced a collaboration with Priority Health to offer the Galleri® multi-cancer early detection blood test to Priority Health’s self-insured employer groups. Priority Health, which began covering Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025, is the first Michigan health plan to enable employer groups to easily add Galleri to existing cancer screening benefits for more than 1.4 million members.
GRAIL (Nasdaq: GRAL) closed a $110 million equity financing with Samsung entities, which purchased common stock at $70.05 per share. The funds are intended to support growth, extend cash runway, and back regulatory and reimbursement efforts for the Galleri multi-cancer early detection test.
GRAIL and Samsung C&T plan to commercialize Galleri in South Korea and may expand to Japan and Singapore, subject to regulatory approvals and other conditions. Initial testing will continue at GRAIL's North Carolina clinical laboratory.
GRAIL (Nasdaq: GRAL) reported full PATHFINDER 2 results in 35,878 adults 50+ using the Galleri multi-cancer early detection blood test alongside standard screenings.
Adding Galleri increased screen-detected cancers up to 6.5-fold, with high specificity, 60.3% positive predictive value, strong episode sensitivity, and low invasive procedure rates.
GRAIL (Nasdaq: GRAL) reported full NHS-Galleri trial results at the 2026 ASCO Meeting. In 142,250 adults screened annually with the Galleri blood test plus standard screening versus standard screening alone, the primary endpoint—a reduction in combined Stage III/IV diagnoses in 12 cancers—was not met.
However, a pre-specified secondary endpoint showed Stage IV diagnoses for these cancers fell by 9%, 22% and 26% in the first, second and third rounds, for a 14% overall reduction. Stage I-II diagnoses rose 16%, screen-detected cancers increased four-fold, emergency-presenting cancers declined 25%, and no serious related adverse events were reported.